Global Systemic Scleroderma Treatment Market Analysis Report 2022

Posted by sandeep gade on November 30th, 2022

In 2021, the systemic scleroderma treatment market was valued at nearly US$ 749.4 Mn, and is estimated to expand at a CAGR of 8% over the forecast period (2022-2032). Market growth is majorly attributed to the presence of innovative small molecule therapies, increasing clinical trials for concerned diseases, and significant government-backed funding. Furthermore, existing industrial and academic collaborations in developed countries are propelling systemic scleroderma treatment market growth.

The treatment for systemic scleroderma has been restricted to the off-label use of generic agents from other indications. However, recently, there has been a major shift in the market for this disease. Many researchers and sponsors are developing novel drugs for the treatment of scleroderma.

In 2019, in the U.S. and Japan, Boehringer Ingelheim’s Ofev (nintedanib) was launched at a global level.

In 2020, the European Commission approved nintedanib as a first therapy for the treatment of progressive systemic scleroderma-associated interstitial lung disease (SSc-ILD).

In 2021, Roche/Genentech’s Actemra/RoActemra (tocilizumab) was approved in the U.S. for further expansion in the treatment of this disease.

Launching and approvals of novel drugs and therapies in recent years are positively impacting the systemic scleroderma treatment market, with more drugs in the pipeline and upcoming launching stages.

Key Takeaways from Market Study

•          By treatment type, drug therapy is expected to hold over 95% market share by the end of 2032.
•          The skin fibrosis segment is leading with nearly one-fourth market share in 2022.
•          Injectables are expected to hold the largest share of 47.7% in 2022 amongst other routes of administration.
•          Hospital pharmacies will dominate the global market with a value share of 41.4% in 2022.
•          By region, North America is forecasted to be the leading regional market with a share of 51.8% by the end of 2032.

“Rising prevalence of systemic scleroderma, increasing R&D activities, and launch of novel therapeutics systemic scleroderma treatment procedures are favouring market expansion,” says an analyst of Persistence Market Research.

 Buy Full Report Now and Get Up to 20% Discount: https://www.persistencemarketresearch.com/checkout/33054